AG˹ٷ

STOCK TITAN

[Form 4] MDB Capital Holdings, LLC Class A common Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) filed a Current Report on Form 8-K disclosing the formal voting results from its 16 June 2025 Annual Meeting of Shareholders.

  • Election of directors: All six nominees—Errol De Souza, Regina Graul, Peter M. Hecht, Steven Hyman, Michael Higgins and Dina Katabi—were re-elected, each receiving roughly 1.32�1.34 million votes FOR versus 63�73 thousand AGAINST; 743,285 broker non-votes were recorded.
  • Auditor ratification: Ernst & Young LLP was confirmed for fiscal 2025 with 2,072,684 FOR, 57,547 AGAINST and 147 ABSTAIN.
  • Say-on-pay (advisory): Executive compensation passed (1,312,697 FOR; 78,221 AGAINST; 6,203 ABSTAIN).
  • Say-on-pay frequency: Shareholders favored an annual vote (827,809 one-year vs. 562,965 three-year).
  • Adjournment authority: The option to adjourn, if necessary, also passed (2,036,703 FOR; 84,719 AGAINST; 18,984 ABSTAIN).

The filing is procedural, reinforces existing governance structures and contains no new financial, operational or strategic disclosures likely to affect the company’s near-term outlook.

Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) ha presentato un rapporto corrente sul modulo 8-K comunicando i risultati ufficiali delle votazioni durante l'Assemblea Annuale degli Azionisti del 16 giugno 2025.

  • Elezione dei membri del consiglio: Tutti e sei i candidati—Errol De Souza, Regina Graul, Peter M. Hecht, Steven Hyman, Michael Higgins e Dina Katabi—sono stati rieletti, ricevendo ciascuno circa 1,32�1,34 milioni di voti FAVOREVOLI contro 63�73 mila CONTRARI; sono stati registrati 743.285 voti di intermediazione non espressi.
  • Ratifica del revisore: Ernst & Young LLP è stata confermata come revisore per l'esercizio 2025 con 2.072.684 voti FAVOREVOLI, 57.547 CONTRARI e 147 ASTENUTI.
  • Voto consultivo sulla remunerazione: La politica di compensi esecutivi è stata approvata (1.312.697 FAVOREVOLI; 78.221 CONTRARI; 6.203 ASTENUTI).
  • Frequenza del voto sulla remunerazione: Gli azionisti hanno preferito un voto annuale (827.809 per un anno contro 562.965 per tre anni).
  • Autorizzazione a rinviare l'assemblea: L'opzione di rinviare, se necessario, è stata approvata (2.036.703 FAVOREVOLI; 84.719 CONTRARI; 18.984 ASTENUTI).

La comunicazione è di natura procedurale, conferma le strutture di governance esistenti e non contiene nuove informazioni finanziarie, operative o strategiche che possano influenzare le prospettive a breve termine della società.

Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) presentó un informe actual en el Formulario 8-K revelando los resultados formales de la votación en su Junta Anual de Accionistas del 16 de junio de 2025.

  • Elección de directores: Los seis nominados—Errol De Souza, Regina Graul, Peter M. Hecht, Steven Hyman, Michael Higgins y Dina Katabi—fueron reelegidos, cada uno recibiendo aproximadamente entre 1.32 y 1.34 millones de votos A FAVOR frente a 63�73 mil EN CONTRA; se registraron 743,285 votos de intermediarios no emitidos.
  • Ratificación del auditor: Ernst & Young LLP fue confirmada para el año fiscal 2025 con 2,072,684 votos A FAVOR, 57,547 EN CONTRA y 147 ABSTENCIONES.
  • Voto consultivo sobre remuneración: La compensación ejecutiva fue aprobada (1,312,697 A FAVOR; 78,221 EN CONTRA; 6,203 ABSTENCIONES).
  • Frecuencia del voto sobre remuneración: Los accionistas prefirieron una votación anual (827,809 un año frente a 562,965 tres años).
  • Autoridad para aplazar: La opción para aplazar, si fuera necesario, también fue aprobada (2,036,703 A FAVOR; 84,719 EN CONTRA; 18,984 ABSTENCIONES).

La presentación es de carácter procedimental, refuerza las estructuras de gobernanza existentes y no contiene nuevas divulgaciones financieras, operativas o estratégicas que puedan afectar la perspectiva a corto plazo de la compañía.

Cyclerion Therapeutics, Inc. (나스�: CYCN)� 2025� 6� 16� 주주총회에서� 공식 투표 결과� 공시하는 현재 보고�(Form 8-K)� 제출했습니다.

  • 이사 선출: 후보 6명—Errol De Souza, Regina Graul, Peter M. Hecht, Steven Hyman, Michael Higgins, Dina Katabi—모� 재선되었으며, � 후보� � 132만~134� 표의 찬성표를 받았� 반대� 6.3만~7.3� 표였습니�. 중개� 미투표는 743,285� 기록되었습니�.
  • 감사� 승인: Ernst & Young LLP가 2025 회계연도 감사인으� 승인되었으며, 찬성 2,072,684�, 반대 57,547�, 기권 147표였습니�.
  • 임원 보수� 대� 자문 투표: 임원 보수안이 통과되었습니�(찬성 1,312,697�; 반대 78,221�; 기권 6,203�).
  • 임원 보수 투표 빈도: 주주들은 연간 투표� 선호했습니다(1� 827,809� vs 3� 562,965�).
  • 연기 권한: 필요 � 회의 연기 옵션� 승인되었습니�(찬성 2,036,703�; 반대 84,719�; 기권 18,984�).

이번 제출은 절차� 성격이며 기존� 거버넌스 구조� 강화하는 내용으로, 회사� 단기 전망� 영향� � 만한 새로� 재무, 운영 또는 전략� 공시� 포함하지 않습니다.

Cyclerion Therapeutics, Inc. (Nasdaq : CYCN) a déposé un rapport actuel sur le formulaire 8-K dévoilant les résultats officiels du vote lors de son assemblée annuelle des actionnaires du 16 juin 2025.

  • Élection des administrateurs : Les six candidats � Errol De Souza, Regina Graul, Peter M. Hecht, Steven Hyman, Michael Higgins et Dina Katabi � ont tous été réélus, chacun recevant environ 1,32 à 1,34 million de voix POUR contre 63 à 73 mille CONTRE ; 743 285 votes d'intermédiaires non exprimés ont été enregistrés.
  • Ratification de l'auditeur : Ernst & Young LLP a été confirmé pour l'exercice 2025 avec 2 072 684 voix POUR, 57 547 CONTRE et 147 ABSTENTIONS.
  • Vote consultatif sur la rémunération : La politique de rémunération des dirigeants a été approuvée (1 312 697 POUR ; 78 221 CONTRE ; 6 203 ABSTENTIONS).
  • Fréquence du vote sur la rémunération : Les actionnaires ont préféré un vote annuel (827 809 pour un an contre 562 965 pour trois ans).
  • Autorisation de ajournement : L'option d'ajourner, si nécessaire, a également été adoptée (2 036 703 POUR ; 84 719 CONTRE ; 18 984 ABSTENTIONS).

Le dépôt est de nature procédurale, renforce les structures de gouvernance existantes et ne contient aucune nouvelle divulgation financière, opérationnelle ou stratégique susceptible d'affecter les perspectives à court terme de la société.

Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) hat einen aktuellen Bericht auf Formular 8-K eingereicht, in dem die formellen Abstimmungsergebnisse seiner Hauptversammlung der Aktionäre am 16. Juni 2025 offengelegt werden.

  • Wahl der Direktoren: Alle sechs Nominierten—Errol De Souza, Regina Graul, Peter M. Hecht, Steven Hyman, Michael Higgins und Dina Katabi—wurden wiedergewählt, jeder erhielt etwa 1,32�1,34 Millionen Stimmen Ü gegenüber 63�73 Tausend GEGEN; es wurden 743.285 Broker-Non-Votes verzeichnet.
  • Bestätigung des Wirtschaftsprüfers: Ernst & Young LLP wurde für das Geschäftsjahr 2025 bestätigt mit 2.072.684 Ü, 57.547 GEGEN und 147 ENTHALTUNGEN.
  • Beratende Abstimmung zur Vergütung: Die Vergütung der Geschäftsleitung wurde genehmigt (1.312.697 Ü; 78.221 GEGEN; 6.203 ENTHALTUNGEN).
  • Abstimmungsfrequenz zur Vergütung: Die Aktionäre bevorzugten eine ä Abstimmung (827.809 für ein Jahr gegenüber 562.965 für drei Jahre).
  • Vertagungsbefugnis: Die Option zur Vertagung, falls erforderlich, wurde ebenfalls angenommen (2.036.703 Ü; 84.719 GEGEN; 18.984 ENTHALTUNGEN).

Die Einreichung ist prozeduraler Natur, bestätigt die bestehenden Governance-Strukturen und enthält keine neuen finanziellen, operativen oder strategischen Offenlegungen, die die kurzfristigen Aussichten des Unternehmens beeinflussen könnten.

Positive
  • All six directors re-elected, demonstrating strong shareholder confidence in current leadership.
  • Ernst & Young LLP ratified with 97% support, ensuring audit continuity and minimized reporting risk.
  • Annual say-on-pay frequency adopted, aligning with governance best practices and enhancing investor feedback mechanisms.
Negative
  • None.

Insights

TL;DR: Routine AGM outcomes; board, auditor and pay package all comfortably approved.

Shareholder support exceeded 90% on every director and auditor proposal, signaling continued confidence in the board and management team. The move to an annual say-on-pay cadence aligns with ISS and Glass Lewis best-practice recommendations, potentially improving ongoing engagement with investors. Because the meeting produced no policy changes, capital allocation shifts or leadership turnover, the disclosure is largely procedural and not expected to move valuation multiples or risk perceptions.

TL;DR: Governance status quo preserved; no immediate portfolio action required.

The decisive re-election of directors and ratification of EY eliminate near-term governance overhangs. Vote tallies reveal modest but not concerning dissent on compensation (�5.6% AGAINST), within normal biotech small-cap ranges. While positive for continuity, the absence of financial guidance, pipeline updates or strategic transactions means the event is neutral from a fundamental and catalyst perspective. Positions in CYCN can be maintained; performance drivers remain clinical milestones rather than governance events.

Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) ha presentato un rapporto corrente sul modulo 8-K comunicando i risultati ufficiali delle votazioni durante l'Assemblea Annuale degli Azionisti del 16 giugno 2025.

  • Elezione dei membri del consiglio: Tutti e sei i candidati—Errol De Souza, Regina Graul, Peter M. Hecht, Steven Hyman, Michael Higgins e Dina Katabi—sono stati rieletti, ricevendo ciascuno circa 1,32�1,34 milioni di voti FAVOREVOLI contro 63�73 mila CONTRARI; sono stati registrati 743.285 voti di intermediazione non espressi.
  • Ratifica del revisore: Ernst & Young LLP è stata confermata come revisore per l'esercizio 2025 con 2.072.684 voti FAVOREVOLI, 57.547 CONTRARI e 147 ASTENUTI.
  • Voto consultivo sulla remunerazione: La politica di compensi esecutivi è stata approvata (1.312.697 FAVOREVOLI; 78.221 CONTRARI; 6.203 ASTENUTI).
  • Frequenza del voto sulla remunerazione: Gli azionisti hanno preferito un voto annuale (827.809 per un anno contro 562.965 per tre anni).
  • Autorizzazione a rinviare l'assemblea: L'opzione di rinviare, se necessario, è stata approvata (2.036.703 FAVOREVOLI; 84.719 CONTRARI; 18.984 ASTENUTI).

La comunicazione è di natura procedurale, conferma le strutture di governance esistenti e non contiene nuove informazioni finanziarie, operative o strategiche che possano influenzare le prospettive a breve termine della società.

Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) presentó un informe actual en el Formulario 8-K revelando los resultados formales de la votación en su Junta Anual de Accionistas del 16 de junio de 2025.

  • Elección de directores: Los seis nominados—Errol De Souza, Regina Graul, Peter M. Hecht, Steven Hyman, Michael Higgins y Dina Katabi—fueron reelegidos, cada uno recibiendo aproximadamente entre 1.32 y 1.34 millones de votos A FAVOR frente a 63�73 mil EN CONTRA; se registraron 743,285 votos de intermediarios no emitidos.
  • Ratificación del auditor: Ernst & Young LLP fue confirmada para el año fiscal 2025 con 2,072,684 votos A FAVOR, 57,547 EN CONTRA y 147 ABSTENCIONES.
  • Voto consultivo sobre remuneración: La compensación ejecutiva fue aprobada (1,312,697 A FAVOR; 78,221 EN CONTRA; 6,203 ABSTENCIONES).
  • Frecuencia del voto sobre remuneración: Los accionistas prefirieron una votación anual (827,809 un año frente a 562,965 tres años).
  • Autoridad para aplazar: La opción para aplazar, si fuera necesario, también fue aprobada (2,036,703 A FAVOR; 84,719 EN CONTRA; 18,984 ABSTENCIONES).

La presentación es de carácter procedimental, refuerza las estructuras de gobernanza existentes y no contiene nuevas divulgaciones financieras, operativas o estratégicas que puedan afectar la perspectiva a corto plazo de la compañía.

Cyclerion Therapeutics, Inc. (나스�: CYCN)� 2025� 6� 16� 주주총회에서� 공식 투표 결과� 공시하는 현재 보고�(Form 8-K)� 제출했습니다.

  • 이사 선출: 후보 6명—Errol De Souza, Regina Graul, Peter M. Hecht, Steven Hyman, Michael Higgins, Dina Katabi—모� 재선되었으며, � 후보� � 132만~134� 표의 찬성표를 받았� 반대� 6.3만~7.3� 표였습니�. 중개� 미투표는 743,285� 기록되었습니�.
  • 감사� 승인: Ernst & Young LLP가 2025 회계연도 감사인으� 승인되었으며, 찬성 2,072,684�, 반대 57,547�, 기권 147표였습니�.
  • 임원 보수� 대� 자문 투표: 임원 보수안이 통과되었습니�(찬성 1,312,697�; 반대 78,221�; 기권 6,203�).
  • 임원 보수 투표 빈도: 주주들은 연간 투표� 선호했습니다(1� 827,809� vs 3� 562,965�).
  • 연기 권한: 필요 � 회의 연기 옵션� 승인되었습니�(찬성 2,036,703�; 반대 84,719�; 기권 18,984�).

이번 제출은 절차� 성격이며 기존� 거버넌스 구조� 강화하는 내용으로, 회사� 단기 전망� 영향� � 만한 새로� 재무, 운영 또는 전략� 공시� 포함하지 않습니다.

Cyclerion Therapeutics, Inc. (Nasdaq : CYCN) a déposé un rapport actuel sur le formulaire 8-K dévoilant les résultats officiels du vote lors de son assemblée annuelle des actionnaires du 16 juin 2025.

  • Élection des administrateurs : Les six candidats � Errol De Souza, Regina Graul, Peter M. Hecht, Steven Hyman, Michael Higgins et Dina Katabi � ont tous été réélus, chacun recevant environ 1,32 à 1,34 million de voix POUR contre 63 à 73 mille CONTRE ; 743 285 votes d'intermédiaires non exprimés ont été enregistrés.
  • Ratification de l'auditeur : Ernst & Young LLP a été confirmé pour l'exercice 2025 avec 2 072 684 voix POUR, 57 547 CONTRE et 147 ABSTENTIONS.
  • Vote consultatif sur la rémunération : La politique de rémunération des dirigeants a été approuvée (1 312 697 POUR ; 78 221 CONTRE ; 6 203 ABSTENTIONS).
  • Fréquence du vote sur la rémunération : Les actionnaires ont préféré un vote annuel (827 809 pour un an contre 562 965 pour trois ans).
  • Autorisation de ajournement : L'option d'ajourner, si nécessaire, a également été adoptée (2 036 703 POUR ; 84 719 CONTRE ; 18 984 ABSTENTIONS).

Le dépôt est de nature procédurale, renforce les structures de gouvernance existantes et ne contient aucune nouvelle divulgation financière, opérationnelle ou stratégique susceptible d'affecter les perspectives à court terme de la société.

Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) hat einen aktuellen Bericht auf Formular 8-K eingereicht, in dem die formellen Abstimmungsergebnisse seiner Hauptversammlung der Aktionäre am 16. Juni 2025 offengelegt werden.

  • Wahl der Direktoren: Alle sechs Nominierten—Errol De Souza, Regina Graul, Peter M. Hecht, Steven Hyman, Michael Higgins und Dina Katabi—wurden wiedergewählt, jeder erhielt etwa 1,32�1,34 Millionen Stimmen Ü gegenüber 63�73 Tausend GEGEN; es wurden 743.285 Broker-Non-Votes verzeichnet.
  • Bestätigung des Wirtschaftsprüfers: Ernst & Young LLP wurde für das Geschäftsjahr 2025 bestätigt mit 2.072.684 Ü, 57.547 GEGEN und 147 ENTHALTUNGEN.
  • Beratende Abstimmung zur Vergütung: Die Vergütung der Geschäftsleitung wurde genehmigt (1.312.697 Ü; 78.221 GEGEN; 6.203 ENTHALTUNGEN).
  • Abstimmungsfrequenz zur Vergütung: Die Aktionäre bevorzugten eine ä Abstimmung (827.809 für ein Jahr gegenüber 562.965 für drei Jahre).
  • Vertagungsbefugnis: Die Option zur Vertagung, falls erforderlich, wurde ebenfalls angenommen (2.036.703 Ü; 84.719 GEGEN; 18.984 ENTHALTUNGEN).

Die Einreichung ist prozeduraler Natur, bestätigt die bestehenden Governance-Strukturen und enthält keine neuen finanziellen, operativen oder strategischen Offenlegungen, die die kurzfristigen Aussichten des Unternehmens beeinflussen könnten.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
MARLETT CHRISTOPHER A

(Last) (First) (Middle)
14135 MIDWAY ROAD,
SUITE G-150

(Street)
ADDISON, TX 75001

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
MDB Capital Holdings, LLC [ MDBH ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director X 10% Owner
X Officer (give title below) Other (specify below)
Co-Founder
3. Date of Earliest Transaction (Month/Day/Year)
06/20/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 06/20/2025 P 888 A $4.13(2) 143,558 I(1) CUST
Common Stock 06/23/2025 P 677 A $4.12 144,235 I(1) CUST
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Held as custodian for minor
2. The reported price in Column 4 is an average purchase price. The shares acquired on June 20, 2025 were purchased in multiple transactions at prices ranging from $4.095 to $4.23 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
/s/ Christopher Marlett 06/24/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What were the 2025 director election results for CYCN?

Each of the six nominees received roughly 1.32�1.34 million votes FOR, with 63-73 thousand AGAINST, and were re-elected.

Did Cyclerion shareholders approve executive compensation in 2025?

Yes. Say-on-pay passed with 1,312,697 FOR, 78,221 AGAINST and 6,203 ABSTAIN votes.

How often will Cyclerion hold future say-on-pay votes?

Shareholders chose an annual advisory vote on executive compensation (827,809 votes for one-year frequency).

Was Ernst & Young retained as Cyclerion's auditor for 2025?

Yes. EY was ratified with 2,072,684 FOR, 57,547 AGAINST and 147 ABSTAIN votes.

Does the Form 8-K include new financial performance data?

No. The filing is limited to shareholder voting results and contains no earnings or pipeline updates.
MDB Capital Holdings LLC-A

NASDAQ:MDBH

MDBH Rankings

MDBH Latest News

MDBH Latest SEC Filings

MDBH Stock Data

42.79M
4.38M
5.04%
3.86%
0.06%
Capital Markets
Finance Services
United States
DALLAS